Canagliflozin Targeting Vascular Inflammation

Sponsor
Ottawa Heart Institute Research Corporation
Study ID
NCT05427084
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Coronary Artery Disease
  • Diabetes Type 2

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Canagliflozin — DRUG
    Canagliflozin tablet 300mg PO daily
  • Placebo — DRUG
    Placebo tablet

Study Details

CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.

Key Dates

Start date
Nov 15, 2024
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Active
    Canagliflozin 300mg PO daily
  • Placebo Comparator: Placebo
    Placebo PO daily

Primary Outcome Measure

TBR (Tissue-to-blood ratio) of the most-diseased segment (MDS) of the ascending aorta [ Time Frame: 6 months ]

Central Contacts

Related Studies